Prognostic analysis of extended field intensity-modulated radiation therapy for cervical cancer
Zhang Feng, Du Xiaomeng, Huang Manni
Department of Gynecologic Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,China (Zhang F,Huang MN);Department of Gynecologic Oncology,Beijing Obstetrics and Gynecology Hospital,Capital Medical University,Beijing 100020,China (Du XM)
Abstract：In recent decades,accurate radiotherapy has developed rapidly,and the application of intensity-modulated radiation therapy (IMRT) in gynecologic malignancies has increased gradually in the past ten years. Many studies have shown a high rate of occult abdominal aortic lymph node metastasis in patients with advanced cervical cancer,while pelvic and abdominal aortic lymph node status are important prognostic factors in cervical cancer patients. Conventional prophylactic extended field radiotherapy has the characteristics of severe gastrointestinal side effects,and synchronic chemotherapy is also controversial. The optimal dose of radiation therapy for metastatic pelvic and abdominal aortic lymph nodes is still controversial. This paper mainly analyzed the effect of prophylactic extended conformal radiotherapy with concurrent chemotherapy on the prognosis of cervical cancer and the dose-effect relationship of lymph node positive region.
Zhang Feng,Du Xiaomeng,Huang Manni. Prognostic analysis of extended field intensity-modulated radiation therapy for cervical cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(3): 323-326.
[1] Wagner A,JhingranA,Gaffney D.Intensity modulated radiotherapy in gynecologic cancers:hope,hype or hyperbole?[J].Gynecol Oncol,2013,130(1):229-236.DOI:10.1016/j.ygyno.2013.04.052. [2] Berman ML,Keys H,Creasman W,et al. Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes:a Gynecologic Oncology Group study[J].Gynecol Oncol,1984,19(1):8-16.DOI:10.1016/0090-8258(84)90151-3. [3] Stehman FB,Bundy BN,DiSaia PJ,et al. Carcinoma of the cervixtreated with radiationtherapy. IA multi-variate analysis ofprognostic variables in the Gynecologic Oncology Group[J].Cancer,1991,67(77):2776-2785. [4] Toita T,Nakano M,Higashi M,et al. Prognostic value of cervicalsize and pelvic lymph node status assessed by computed tomography for patients with uterine cervical cancer treated by radical radiation therapy[J].Int J Radiat Oncol Biol Phys,1995,33(4):843-849.DOI:10.1016/0360-3016(95)00204-5. [5] Stehman FB,Perez CA,Kurman RJ,et al. Uterine cervix[A]//Hoskins WJ,Perez CA,Young RC.Principles and practice of gynecologic oncology[M].2nd ed. Philadelphia,PA:Lippincott-Raven Press,1997:785-857. [6] Fletcher GH,Rutledge FN.Extended field technique in the management of the cancers of the uterine cervix[J].Am J Roentgenol Radium Nucl Med,1972,114(1):116-122. [7] Zhang GY,He FF,Fu CL,et al. Definitive extended field intensity-modulated radiotherapy and concurrent cisplatin chemosensitization in the treatment of IB2-ⅢB cervical cancer[J].J Gynecol Oncol,2014,25(1):14-21.DOI:10.3802/jgo.2014.25.1.14. [8] Tseng JY,Yen MS,Twu NF,et al. Prognostic nomogram for overall survival in stage ⅡB-IVA cervical cancer patients treated with concurrent chemoradiotherapy[J].Am J Obstet Gynecol,2010,202(2):174.e1-174.e7.DOI:10.1016/j.ajog.2009.09.028. [9] Hong JH,Tsai CS,Lai CH,et al. Risk stratification of patients with advanced squamous cell carcinoma of cervix treated by radiotherapy alone[J].Int J Radiat Oncol Biol Phys,2005,63(2):492-499.DOI:10.1016/j.ijrobp.2005.02.012. [10] Goff BA,Muntz HG,Paley PJ,et al. Impact of surgical staging in women with locally advanced cervical cancer[J].Gynecol Oncol,1999,74(3):436-442. [11] Choi HJ,Ju W,Myung SK,et al. Diagnostic performance of computer tomography,magnetic resonance imaging,and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer:meta-analysis[J].Cancer Sci,2010,101(6):1471-1479.DOI:10.1111/j.1349-7006.2010.01532.x. [12] Kidd EA,Siegel BA,Dehdashti F,et al. Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer[J].Int J Radiat Oncol Biol Phys,2010,77(4):1085-1091.DOI:10.1016/j.ijrobp.2009.06.041. [13] Salem A,Salem AF,Al-Ibraheem A,et al. Evidence for the use PET for radiation therapy planning in patients with cervicalcancer:a systematic review[J].Hematol Oncol Stem Cell Ther,2011,4(4):173-181.DOI:10.5144/1658-3876.2011.173. [14] Gouy S,Morice P,Narducci F,et al. Nodal-staging surgery for locally advanced cervical cancer in the era of PET[J].Lancet Oncol,2012,13(5):e212-e220.DOI:10.1016/S1470-2045(12)70011-6. [15] Ramirez PT,Jhingran A,Macapinlac HA,et al. Laparoscopic extraperitonealpara-aortic lymphadenectomy in locally advanced cervical cancer:a prospective correlation of surgical findings with positron emission tomography/computed tomography findings[J].Cancer,2011,117(9):1928-1934.DOI:10.1002/cncr.25739. [16] Malfetano JH,Keys H,Cunningham MJ,et al. Extended fieldradiation and cisplatinfor stage ⅡB and ⅢB cervical carcinoma[J].Gynecol Oncol,1997,67(2):203-207.DOI:10.1006/gyno.1997.4865. [17] Jones WB,Shingleton HM,Russell A,et al. Patterns of care for invasivecervical cancer. Results of a national survey of 1984 and 1990[J].Cancer,1995,76(10Suppl):1934-1947.DOI:10.1002/1097-0142(19951115)76:10+<1934::AID-CNCR2820761310>3.0.CO;2-8. [18] Eifel PJ,Winter K,Morris M,et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and Para-aorticirradiation for high-risk cervical cancer:an update of radiation therapy oncology group trial (RTOG) 90-01[J].J Clin Oncol,2004,22(5):872-880.DOI:10.1200/JCO.2004.07.197. [19] Liang JA,Chen SW,Hung YC,et al. Low-dose,prophylactic,extended-field,intensity-modulated radiotherapy plus concurrent weekly cisplatinfor patients with stage ⅠB2-ⅢB cervical cancer,positive pelvic lymph nodes,and negative para-aortic lymph nodes[J].Int J Gynecol Cancer,2014,24(5):901-907.DOI:10.1097/IGC.0b013e31829f4 dc5. [20] Lee J,Lin JB,Chang CL,et al,Prophylactic lower Para-aortic irradiation using intensity-modulated radiotherapymitigates the risk of Para-aorticrecurrence in locallyadvanced cervical cancer:a 10-year institutional experience[J].Gynecol Oncol,2017,146(1):20-26.DOI:10.1016/j.ygyno.2017.04.016. [21] Rotman M,Pajak TF,Choi K,et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages ⅡB and bulky ⅠB and ⅡA cervical carcinomas.ten-year treatment results of RTOG 79-20[J].JAMA,1995,274(5):387-393.DOI:10.1001/jama.1995.03530050035029. [22] Portelance L,Chao KSC,Grigsby PW,et al. Intensity-modulated radiation therapy (IMRT) reduces small bowel,rectum,and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation[J].Int J Radiat Oncol Biol Phys,2001,51(1):261-266.DOI:10.1016/S0360-3016(01)01664-9. [23] Rose PG,Adler LP,Rodriguez M,et al. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging:a surgicopathologic study[J].J Clin Oncol,1999,17(1):41-45.DOI:10.1200/JCO.1999.17.1.41. [24] Grigsby PW,Siegel BA,Dehdashti F.Lymph node staging by positron emission tomography in patients with carcinoma of the cervix[J].J Clin Oncol,2001,19(17):3745-3749.DOI:10.1200/JCO.2001.19.17.3745. [25] Kidd EA,Siegel BA,Dehdashti F,et al. Lymph node staging by positron emission tomography in cervical cancer:relationship to prognosis[J].J Clin Oncol,2010,28(12):2108-2113.DOI:10.1200/JCO.2009.25.4151. [26] Wright JD,Dehdashti F,Herzog TJ,et al. Preoperative lymph node staging of early-stagecervical carcinoma by[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography[J].Cancer,2005,104(11):2484-2491.DOI:10.1002/cncr.21527. [27] Schwarz JK,Siegel BA,Dehdashti F,et al. Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer[J].Int J Radiat Oncol Biol Phys,2012,83(1):185-190.DOI:10.1016/j.ijrobp.2011.05.053. [28] Beriwal S,Kannan N,Sukumvanich P,et al. Complete metabolic response after definitive radiation therapy for cervical cancer:patterns and factors predicting for recurrence[J].Gynecol Oncol,2012,127(2):303-306.DOI:10.1016/j.ygyno.2012.08.006. [29] Yoon MS,Ahn SJ,Nah BS,et al. Metabolic response of lymph nodes immediately after RT is related with survival outcome of patients with pelvic node-positive cervical cancer using consecutive[18F]fluorodeoxyglucose-positron emission tomography/computed tomography[J].Int J Radiat Oncol Biol Phys,2012,84(4):e491-e497.DOI:10.1016/j.ijrobp.2012.05.041. [30] Rash DL,Lee YC,Kashefi A,et al. Clinical response of pelvic and para-aortic lymphadenopathy to a radiation boost in the definitive management of locally advanced cervical cancer[J].Int J Radiat Oncol Biol Phys,2013,87(2):317-322.DOI:10.1016/j.ijrobp.2013.06.2031. [31] Ahmed RS,Kim RY,Duan J,et al. IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk[J].Int J Radiat Oncol Biol Phys,2004,60(2):505-512.DOI:10.1016/j.ijrobp.2004.03.035. [32] Wakatsuki M,Ohno T,Kato S,et al. Impact of boost irradiation on pelvic lymph node control in patients with cervical cancer[J].J Radiat Res,2014,55(1):139-145.DOI:10.1093/jrr/rrt097. [33] Du XL,Sheng XG,Jiang T,et al. Intensity-modulated radiationtherapy versus para-aorticfield radiotherapy to treatpara-aortic lymph node metastasis in cervical cancer:prospective study[J].Croat Med J,2010,51(3):229-236.DOI:10.3325/cmj.2010.51.229. [34] Gerszten K,Colonello K,Heron DE,et al. Feasibility of concurrent cisplatin and extended field radiation therapy (EFRT) using intensity-modulated radiotherapy (IMRT) for carcinoma of the cervix[J].Gynecol Oncol,2006,102(2):182-188.DOI:10.1016/j.ygyno.2005.12.044. [35] Kim YS,Kim JH,Ahn SD,et al. High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive Para-aorticlymph nodes[J].Int J Radiat Oncol Biol Phys,2009,74(5):1522-1528.DOI:10.1016/j.ijrobp.2008.10.024. [36] Jensen LG,Hasselle MD,Rose BS,et al. Outcomes for patients with cervical cancer treated with extended-field intensity-modulated radiation therapy and concurrent cisplatin[J].Int J Gynecol Cancer,2013,23(1):119-125.DOI:10.1097/IGC.0b013e3182749114.
2018, Vol. 27 
